Despite macroeconomic challenges, the biotech industry has been performing relatively well. Government initiatives, rapid technology breakthroughs, and inelastic demand for healthcare are fostering the growth of the biotech industry.
So, investors could consider buying shares of Gilead Sciences, Inc. (GILD) and Vertex Pharmaceuticals Incorporated (VRTX) in March, which should generate stable returns despite the market uncertainties.
